ADAPY (Adaptimmune Therapeutics) EV-to-OCF: -0.16 (As of Aug. 26, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Adaptimmune Therapeutics EV-to-OCF?

Adaptimmune Therapeutics ADAPY +5.80% EV-to-OCF is -0.16 as of Aug. 26, 2026.

EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Adaptimmune Therapeutics's Enterprise Value is $29.63 Mil. Adaptimmune Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2025 was $-190.03 Mil. Therefore, Adaptimmune Therapeutics's EV-to-OCF for today is -0.16.

The historical rank and industry rank for Adaptimmune Therapeutics's EV-to-OCF or its related term are showing as below:

ADAPY' s EV-to-OCF Range Over the Past 10 Years
Min: -24.22   Med: -2.62   Max: 22.53
Current: -0.16

During the past 13 years, the highest EV-to-OCF of Adaptimmune Therapeutics was 22.53. The lowest was -24.22. And the median was -2.62.

ADAPY's EV-to-OCF is not ranked
in the Biotechnology industry.
Industry Median: -3.71 vs ADAPY: -0.16

EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2026-08-26), Adaptimmune Therapeutics's stock price is $0.02645. Adaptimmune Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2025 was $-0.674. Therefore, Adaptimmune Therapeutics's PE Ratio (TTM) for today is At Loss.

Adaptimmune Therapeutics  (OTCPK:ADAPY) EV-to-OCF Explanation

EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Adaptimmune Therapeutics's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.02645/-0.674
=At Loss

Adaptimmune Therapeutics's share price for today is $0.02645.
Adaptimmune Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.674.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.

Adaptimmune Therapeutics EV-to-OCF Related Terms

Adaptimmune Therapeutics EV-to-OCF Historical Data

* Premium members only.

The historical data trend for Adaptimmune Therapeutics's EV-to-OCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adaptimmune Therapeutics EV-to-OCF Chart

Adaptimmune Therapeutics Annual Data
Trend Jun15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-OCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -9.14 22.54 -0.41 -0.41 -0.83

Adaptimmune Therapeutics Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25
EV-to-OCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.84 -2.45 -0.83 -0.37 -0.45

ADAPY vs BCLI, APRE, JSPR: EV-to-OCF Comparison

For the Biotechnology subindustry, Adaptimmune Therapeutics's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Adaptimmune Therapeutics EV-to-OCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adaptimmune Therapeutics's EV-to-OCF distribution charts can be found below:

* The bar in red indicates where Adaptimmune Therapeutics's EV-to-OCF falls into.


Adaptimmune Therapeutics EV-to-OCF Calculation

Adaptimmune Therapeutics's EV-to-OCF for today is calculated as:

EV-to-OCF=Enterprise Value (Today)/Cash Flow from Operations (TTM)
=29.629/-190.027
=-0.16

Adaptimmune Therapeutics's current Enterprise Value is $29.63 Mil.
Adaptimmune Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-190.03 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EV-to-OCF →
What does a EV-to-OCF of -0.16 mean?
Adaptimmune Therapeutics (ADAPY) has a EV-to-OCF of -0.16 as of Aug. 26, 2026.
Is Adaptimmune Therapeutics' EV-to-OCF too high?
Adaptimmune Therapeutics' current EV-to-OCF is -0.16.
How does Adaptimmune Therapeutics' EV-to-OCF compare to BCLI and APRE?
Adaptimmune Therapeutics' EV-to-OCF of -0.16 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Adaptimmune Therapeutics's current EV-to-OCF is -0.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adaptimmune Therapeutics stock overvalued right now?
Adaptimmune Therapeutics (ADAPY) has a current EV-to-OCF of -0.16. The current EV-to-OCF is -0.16. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Adaptimmune Therapeutics (ADAPY), the current EV-to-OCF is -0.16 as of Aug. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Adaptimmune Therapeutics Business Description

Other Exchanges 473A:Germany
Address 99 Park Drive, Milton Park, The Innovation Centre, Abingdon, Oxfordshire, GBR, OX14 4RY
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its product pipelines include ADP-600 [PRAME] and ADP-520 [CD70].